These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 19707309)

  • 1. Targeted therapies in the management of metastatic bladder cancer.
    Fassan M; Trabulsi EJ; Gomella LG; Baffa R
    Biologics; 2007 Dec; 1(4):393-406. PubMed ID: 19707309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of metastatic bladder cancer.
    Nadal R; Bellmunt J
    Cancer Treat Rev; 2019 Jun; 76():10-21. PubMed ID: 31030123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging biomarkers and targeted therapies in urothelial carcinoma.
    Mendiratta P; Grivas P
    Ann Transl Med; 2018 Jun; 6(12):250. PubMed ID: 30069452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular biology and targeted therapies for urothelial carcinoma.
    Seront E; Machiels JP
    Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of bladder cancer: current and emerging strategies.
    Agarwal N; Hussain M
    Drugs; 2009 Jun; 69(9):1173-87. PubMed ID: 19537835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
    Millis SZ; Bryant D; Basu G; Bender R; Vranic S; Gatalica Z; Vogelzang NJ
    Clin Genitourin Cancer; 2015 Feb; 13(1):e37-49. PubMed ID: 25178641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets.
    Abdeltwab RM; Yacoub E; Rashad AH; Shohdy KS
    Bladder Cancer; 2023; 9(4):313-322. PubMed ID: 38994247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
    Sternberg CN; Donat SM; Bellmunt J; Millikan RE; Stadler W; De Mulder P; Sherif A; von der Maase H; Tsukamoto T; Soloway MS
    Urology; 2007 Jan; 69(1 Suppl):62-79. PubMed ID: 17280909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting FGFR in bladder cancer: ready for clinical practice?
    De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
    Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
    [No Abstract]   [Full Text] [Related]  

  • 10. Understanding the biology of urothelial cancer metastasis.
    Kobayashi T
    Asian J Urol; 2016 Oct; 3(4):211-222. PubMed ID: 29264189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs and new approaches in metastatic bladder cancer.
    Bellmunt J; de Wit R; Albiol S; Tabernero J; Albanell J; Baselga J
    Crit Rev Oncol Hematol; 2003 Aug; 47(2):195-206. PubMed ID: 12900012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
    Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J
    Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer.
    Giridhar KV; Kohli M
    Mayo Clin Proc; 2017 Oct; 92(10):1564-1582. PubMed ID: 28982487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the management of urothelial carcinoma: is immunotherapy the answer?
    Santopietro AL; Einstein D; Bellmunt J
    Expert Opin Pharmacother; 2021 Sep; 22(13):1743-1759. PubMed ID: 33905290
    [No Abstract]   [Full Text] [Related]  

  • 16. Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review.
    Nelson BE; Hong A; Jana B
    Front Oncol; 2021; 11():705294. PubMed ID: 34422659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions.
    Gupta S; Gill D; Poole A; Agarwal N
    Cancers (Basel); 2017 Jan; 9(2):. PubMed ID: 28134806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic targets in advanced urothelial carcinoma.
    Rouanne M; Loriot Y; Lebret T; Soria JC
    Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.